Rethinking RCC Surveillance: Is Less Really More?
"A New Perspective on Renal Cell Carcinoma Follow-Up"
For individuals who've battled localized renal cell carcinoma (RCC), the journey doesn't quite end with the final surgery. Oncologic surveillance—regular check-ups and tests—becomes the new normal. But here's the catch: there's surprisingly little hard evidence to guide exactly how much surveillance is needed. This is largely based on the idea that by keeping a close eye on things, recurrence is caught early, leading to better outcomes. However, this approach may not always be the best one.
Several organizations have developed their own sets of surveillance guidelines for RCC, including the European Association of Urology (EAU), the National Comprehensive Cancer Network (NCCN), and others. The challenge, however, lies in the lack of high-quality evidence to back a specific frequency, duration, or type of surveillance testing. The result is a lack of consensus, leaving doctors and patients to navigate this phase with uncertainty.
Against this backdrop of uncertainty, research is stepping in to find the path forward. A recent study by Dabestani et al., published in European Urology, is stirring up the debate. It questions whether more intensive imaging during follow-up truly provides a benefit for patients who have undergone surgery for localized RCC. Their findings suggest that the answer isn't as straightforward as we might think.
Why Surveillance Matters
RCC surveillance is intended to identify recurrence while balancing the burdens of repeated imaging, testing, and clinical visits. Its value may differ according to tumor characteristics, treatment history, recurrence risk, and patient preferences. Because the available evidence does not establish one universally optimal intensity, surveillance decisions are best understood as individualized and potentially subject to shared decision-making.
Balancing Follow-Up
Standard RCC follow-up commonly combines clinical assessment with laboratory testing and imaging, but the exact schedule can vary. More intensive surveillance may provide additional opportunities to detect recurrence, while also increasing costs, inconvenience, and exposure to medical procedures. Less intensive follow-up may reduce those burdens, although uncertainty can remain about whether clinically important recurrence will be detected promptly.
An Evolving Field
The changing face of renal-cell carcinoma has been shaped by improved understanding of RCC, its local and systemic management, and controversies spanning diagnosis through intervention. A historical timeline described by Bhatt and Finelli traces landmarks in RCC diagnosis and treatment across four centuries, while later reviews describe fundamental changes in the management of localized and advanced disease. Contemporary follow-up guidance reflects this evolving evidence base: the American Urological Association states that each visit should include relevant history, physical examination, laboratory testing, and abdominal and chest imaging. The same guidance reports that 30% of renal cancer recurrences after surgery are diagnosed beyond 60 months and recommends informed, shared decision-making about surveillance beyond that point.
The Great Imaging Debate: How Much is Too Much?
The study delved into the RECUR database, a collection of information from 12 centers across eight European countries. The researchers looked at 336 RCC recurrences that were surgically treated between 2006 and 2011. They aimed to determine the number of images needed to spot recurrences and whether more imaging led to better survival rates. The question: Did patients who underwent more frequent imaging, as compared to the 2017 EAU guidelines, fare better?
- Quantity vs. Quality: It took 52 imaging procedures to detect a single recurrence.
- Resource Intensive: Identifying a recurrence-free, high-risk patient required 697 images.
- No Survival Advantage: More intensive imaging didn't significantly improve overall survival.
Toward More Adaptive Surveillance
Recent RCC research emphasizes that the disease is highly heterogeneous, with diverse molecular alterations and dynamic evolutionary trajectories. Nature describes RCC as a heterogeneous group of cancers originating in the proximal convoluted tubule of the kidney, with clear cell among its three most common forms. Reviews of postoperative surveillance examine how prognostic factors and recurrence patterns have shaped existing protocols. A 2025 scoping review found differences in surveillance practice and evidence after nephrectomy or ablation and identified research gaps requiring greater harmonization.
The Risks of Too Much or Too Little
A less-intensive surveillance strategy may reduce testing burdens, but it can also leave uncertainty about whether recurrence will be detected soon enough to influence treatment. Conversely, more frequent follow-up may increase costs, inconvenience, and exposure without guaranteeing better outcomes for every patient. These trade-offs mean that reducing surveillance should not be treated as automatically safer, particularly when individual recurrence risk is uncertain.
Comparing Surveillance Strategies
Published RCC surveillance guidelines can differ in intensity, cost, radiation exposure, and anticipated cancer control after partial nephrectomy. This variation makes guideline choice consequential rather than merely administrative. At the treatment level, a study of well-selected patients with small renal masses suspicious for RCC reported that active surveillance was a safe alternative to surgery or ablation, with noninferior oncological outcomes. The comparison therefore depends on both the follow-up protocol and the clinical context in which surveillance is used.
Time to Rethink RCC Surveillance?
The study by Dabestani et al. highlights a crucial point: more surveillance isn't always better. The current guidelines, which often take a one-size-fits-all approach, may not be the most effective or efficient way to monitor patients after RCC treatment. What's needed is a more individualized strategy that takes into account a patient's specific risk factors, preferences, and overall health. This will allow for a more balanced approach that prioritizes medical necessity and economic sustainability.
A Risk-Adapted Middle Ground
The central question is not whether surveillance should be reduced in every case, but whether its intensity matches the patient's likely risk and circumstances. A risk-adapted approach could avoid unnecessary testing while preserving closer follow-up for situations in which recurrence would be more consequential. Any such approach should remain flexible as new evidence changes understanding of RCC biology and treatment.
Personalizing the Next Phase
Future RCC surveillance may become more individualized as clinicians better distinguish tumors with different biological and clinical trajectories. Research will need to clarify which patients can safely undergo less intensive monitoring and which require longer or closer follow-up. Progress is likely to depend on integrating clinical judgment with more precise evidence rather than applying one schedule to every patient.
Beyond the Schedule
Surveillance decisions are shaped not only by medical evidence but also by access to imaging, laboratory services, specialist care, and consistent follow-up. Differences in available resources can make the same protocol easier to implement for some patients than for others. A durable surveillance strategy therefore needs to consider practical constraints alongside recurrence risk and potential clinical benefit.
Shared Decisions in Practice
Patients may weigh reassurance from frequent monitoring against the time, expense, inconvenience, and anxiety associated with repeated testing. Others may prefer fewer visits but need clear information about the uncertainty that this choice can involve. Meaningful shared decision-making can help align surveillance with the patient's risk profile, preferences, and ability to participate in long-term follow-up.